Klančar Uroš, Baumgartner Saša, Legen Igor, Smrdel Polona, Kampuš Nataša Jeraj, Krajcar Dejan, Markun Boštjan, Kočevar Klemen
Lek Pharmaceuticals d.d, Verovškova 57, 1526, Ljubljana, Slovenia.
AAPS PharmSciTech. 2015 Apr;16(2):398-406. doi: 10.1208/s12249-014-0234-4. Epub 2014 Oct 18.
It is challenging to achieve mechanically robust drug-release profiles from hydrophilic matrices containing a high dose of a drug with good solubility. However, a mechanically robust drug release over prolonged period of time can be achieved, especially if the viscosity and amount of the polymer is sufficiently high, above the "threshold values." The goal of this research was to determine the hydroxypropyl cellulose (HPC) and hydroxypropyl methylcellulose (HPMC) polymer threshold amount that would enable robust drug release from matrix tablets containing a high dose of levetiracetam as a class I model drug according to the Biopharmaceutical Classification System (BCS). For this purpose, formulations containing HPC or HPMC of similar viscosity range, but in different amounts, were prepared. Based on the dissolution results, two final formulations were selected for additional in vitro and in vivo evaluation to confirm the robustness and to show bioequivalence. Tablets were exposed to various stress conditions in vitro with the use of different mechanically stress-inducing dissolution methods. The in vitro results were compared with in vivo results obtained from fasted and fed bioequivalence studies. Under both conditions, the formulations were bioequivalent and food had a negligible influence on the pharmacokinetic parameters C max and area under the curve (AUC). It was concluded that the drug release from both selected formulations is mechanically robust and that HPC and HPMC polymers with intrinsic viscosities above 9 dL/g and in quantities above 30% enable good mechanical resistance, which ensures bioequivalence. In addition, HPC matrices were found to be more mechanically robust compared to HPMC.
从含有高剂量易溶性药物的亲水性基质中实现机械稳定的药物释放曲线具有挑战性。然而,尤其是当聚合物的粘度和用量足够高,高于“阈值”时,可以实现长时间的机械稳定药物释放。本研究的目的是确定羟丙基纤维素(HPC)和羟丙基甲基纤维素(HPMC)聚合物的阈值用量,以使含有高剂量左乙拉西坦(作为生物药剂学分类系统(BCS)中的I类模型药物)的基质片剂实现稳定的药物释放。为此,制备了含有粘度范围相似但用量不同的HPC或HPMC的制剂。根据溶出结果,选择了两种最终制剂进行额外的体外和体内评价,以确认其稳定性并显示生物等效性。使用不同的机械应力诱导溶出方法,使片剂在体外暴露于各种应力条件下。将体外结果与空腹和进食生物等效性研究获得的体内结果进行比较。在这两种条件下,制剂均具有生物等效性,食物对药代动力学参数Cmax和曲线下面积(AUC)的影响可忽略不计。得出的结论是,两种选定制剂的药物释放具有机械稳定性,特性粘度高于9 dL/g且用量高于30%的HPC和HPMC聚合物具有良好的机械抗性,可确保生物等效性。此外,发现HPC基质比HPMC在机械性能上更稳定。